Do analysts rate RENX or COG?

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate INHC or COG?

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than Induction Healthcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Induction Healthcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, COG or IQAI?

IQ-AI has lower revenue, but higher earnings than Cambridge Cognition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cambridge Cognition £9.40M 1.79 -£1.58M -£3.90 N/A IQ-AI £538.19K 3.30 N/A N/A N/A

Is COG or IQAI more profitable?

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets Cambridge Cognition -17.82% -62.89% -0.30% IQ-AI -77.52% -140.75% -22.03%

Cambridge Cognition (COG) Competitors

GBX 31.15 +0.15 (+0.48%)

As of 11:47 AM Eastern

Compare

COG vs. KOO, RENX, INHC, FDBK, and IQAI

Should you buy Cambridge Cognition stock or one of its competitors? Cambridge Cognition's main competitors and comparable companies include Kooth (KOO), Renalytix (RENX), Induction Healthcare Group (INHC), Feedback (FDBK), and IQ-AI (IQAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Cambridge Cognition compare to Kooth?

Cambridge Cognition (LON:COG) and Kooth (LON:KOO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Kooth has a net margin of 4.12% compared to Cambridge Cognition's net margin of -17.82%. Kooth's return on equity of 8.84% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Kooth	4.12%	8.84%	10.12%

Cambridge Cognition currently has a consensus target price of GBX 56, suggesting a potential upside of 79.79%. Kooth has a consensus target price of GBX 330, suggesting a potential upside of 69.23%. Given Cambridge Cognition's higher probable upside, equities analysts plainly believe Cambridge Cognition is more favorable than Kooth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

15.9% of Cambridge Cognition shares are held by institutional investors. Comparatively, 20.9% of Kooth shares are held by institutional investors. 3.2% of Cambridge Cognition shares are held by company insiders. Comparatively, 30.4% of Kooth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kooth has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.79	-£1.58M	-£3.90	N/A
Kooth	£63.29M	1.12	£4.00M	£7.00	27.86

In the previous week, Cambridge Cognition's average media sentiment score of 0.00 equaled Kooth'saverage media sentiment score.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Kooth	Neutral

Cambridge Cognition has a beta of 0.809, meaning that its share price is 19% less volatile than the broader market. Comparatively, Kooth has a beta of 1.286, meaning that its share price is 29% more volatile than the broader market.

Summary

Kooth beats Cambridge Cognition on 11 of the 13 factors compared between the two stocks.

How does Cambridge Cognition compare to Renalytix?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	5.55	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.79	-£1.58M	-£3.90	N/A

Renalytix has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its share price is 19% less volatile than the broader market.

Cambridge Cognition has a consensus target price of GBX 56, suggesting a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Renalytix's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Renalytix	Neutral
Cambridge Cognition	Neutral

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 5.1% of Renalytix shares are owned by insiders. Comparatively, 3.2% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-506.25%	675.00%	-93.54%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Summary

Cambridge Cognition beats Renalytix on 9 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 3.2% of Cambridge Cognition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Cambridge Cognition is more favorable than Induction Healthcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Induction Healthcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has a net margin of -17.82% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.58% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Induction Healthcare Group	-23.86%	-14.58%	-7.32%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

Cambridge Cognition has lower revenue, but higher earnings than Induction Healthcare Group. Cambridge Cognition is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A
Cambridge Cognition	£9.40M	1.79	-£1.58M	-£3.90	N/A

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Cambridge Cognition'saverage media sentiment score.

Company	Overall Sentiment
Induction Healthcare Group	Neutral
Cambridge Cognition	Neutral

Induction Healthcare Group has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, meaning that its stock price is 19% less volatile than the broader market.

Summary

Cambridge Cognition beats Induction Healthcare Group on 9 of the 14 factors compared between the two stocks.

How does Cambridge Cognition compare to Feedback?

Cambridge Cognition (LON:COG) and Feedback (LON:FDBK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Cambridge Cognition has a net margin of -17.82% compared to Feedback's net margin of -845.25%. Cambridge Cognition's return on equity of -62.89% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
Feedback	-845.25%	-135.17%	-22.99%

Cambridge Cognition has a beta of 0.809, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Feedback has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Cambridge Cognition presently has a consensus price target of GBX 56, suggesting a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cambridge Cognition is more favorable than Feedback.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Feedback	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Feedback had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 1 mentions for Feedback and 0 mentions for Cambridge Cognition. Feedback's average media sentiment score of 0.75 beat Cambridge Cognition's score of 0.00 indicating that Feedback is being referred to more favorably in the news media.

Company	Overall Sentiment
Cambridge Cognition	Neutral
Feedback	Positive

15.9% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 24.8% of Feedback shares are owned by institutional investors. 3.2% of Cambridge Cognition shares are owned by insiders. Comparatively, 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cambridge Cognition has higher revenue and earnings than Feedback. Cambridge Cognition is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.79	-£1.58M	-£3.90	N/A
Feedback	£849.62K	3.47	-£10.84M	-£15.74	N/A

Summary

Cambridge Cognition beats Feedback on 10 of the 16 factors compared between the two stocks.

How does Cambridge Cognition compare to IQ-AI?

Cambridge Cognition (LON:COG) and IQ-AI (LON:IQAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

IQ-AI has lower revenue, but higher earnings than Cambridge Cognition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cambridge Cognition	£9.40M	1.79	-£1.58M	-£3.90	N/A
IQ-AI	£538.19K	3.30	N/A	N/A	N/A

Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Cambridge Cognition presently has a consensus target price of GBX 56, indicating a potential upside of 79.79%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cambridge Cognition is more favorable than IQ-AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
IQ-AI	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cambridge Cognition has a net margin of -17.82% compared to IQ-AI's net margin of -77.52%. Cambridge Cognition's return on equity of -62.89% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cambridge Cognition	-17.82%	-62.89%	-0.30%
IQ-AI	-77.52%	-140.75%	-22.03%

15.9% of Cambridge Cognition shares are owned by institutional investors. 3.2% of Cambridge Cognition shares are owned by insiders. Comparatively, 66.0% of IQ-AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cambridge Cognition's average media sentiment score of 0.00 equaled IQ-AI'saverage media sentiment score.

Company	Overall Sentiment
Cambridge Cognition	Neutral
IQ-AI	Neutral

Summary

Cambridge Cognition beats IQ-AI on 9 of the 12 factors compared between the two stocks.

Get Cambridge Cognition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COG vs. The Competition

Export

Metric	Cambridge Cognition	Healthcare Technology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.81M	£1.76B	£7.12B	£2.92B
Dividend Yield	N/A	4.69%	2.53%	6.17%
P/E Ratio	-7.99	21.99	271.82	367.32
Price / Sales	1.79	82.21	687.17	83,333.24
Price / Cash	4.31	31.64	79.17	27.89
Price / Book	4.29	7.49	12.97	6.97
Net Income	-£1.58M	-£26.60M	£3.46B	£5.89B
7 Day Performance	0.48%	2.50%	-0.09%	0.74%
1 Month Performance	-2.74%	13.24%	7.42%	3.34%
1 Year Performance	-5.15%	-13.97%	24.00%	23.04%

Cambridge Cognition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COG Cambridge Cognition	N/A	GBX 31.15 +0.5%	GBX 56 +79.8%	+18.5%	£16.81M	£9.40M	N/A	80	High Trading Volume
KOO Kooth	2.1981 of 5 stars	GBX 145 -1.7%	GBX 330 +127.6%	+2.2%	£53.53M	£63.29M	20.71	478	Gap Up
RENX Renalytix	N/A	GBX 3.74 -4.2%	N/A	-26.5%	£17.04M	£3.30M	N/A	102	Gap Down
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 6.72 -1.9%	N/A	-47.3%	£3.00M	£849.62K	N/A	24	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:COG) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cambridge Cognition (COG) Competitors

COG vs. KOO, RENX, INHC, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Summary

How does Cambridge Cognition compare to Renalytix?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Summary

How does Cambridge Cognition compare to Feedback?

Summary

How does Cambridge Cognition compare to IQ-AI?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cambridge Cognition (COG) Competitors

COG vs. KOO, RENX, INHC, FDBK, and IQAI

How does Cambridge Cognition compare to Kooth?

Is COG or KOO more profitable?

Do analysts recommend COG or KOO?

Do institutionals and insiders have more ownership in COG or KOO?

Which has stronger valuation and earnings, COG or KOO?

Does the media favor COG or KOO?

Which has more volatility & risk, COG or KOO?

Summary

How does Cambridge Cognition compare to Renalytix?

Which has preferable earnings & valuation, RENX or COG?

Which has more risk and volatility, RENX or COG?

Do analysts rate RENX or COG?

Does the media refer more to RENX or COG?

Do insiders & institutionals hold more shares of RENX or COG?

Is RENX or COG more profitable?

Summary

How does Cambridge Cognition compare to Induction Healthcare Group?

Do insiders and institutionals believe in INHC or COG?

Do analysts rate INHC or COG?

Is INHC or COG more profitable?

Which has better earnings & valuation, INHC or COG?

Does the media prefer INHC or COG?

Which has more risk & volatility, INHC or COG?

Summary

How does Cambridge Cognition compare to Feedback?

Is COG or FDBK more profitable?

Which has more volatility and risk, COG or FDBK?

Do analysts prefer COG or FDBK?

Does the media favor COG or FDBK?

Do institutionals & insiders have more ownership in COG or FDBK?

Which has preferable valuation and earnings, COG or FDBK?

Summary

How does Cambridge Cognition compare to IQ-AI?

Which has preferable earnings and valuation, COG or IQAI?

Which has more volatility and risk, COG or IQAI?

Do analysts rate COG or IQAI?

Is COG or IQAI more profitable?

Do institutionals and insiders believe in COG or IQAI?

Does the media prefer COG or IQAI?

Summary

Media Sentiment Over Time

COG vs. The Competition

Cambridge Cognition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools